Q3 2025 Holdings
Filed 2025-11-14 | 91 holdings | $13.8B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| BeOne Medicines Ltd.(ONC) | SPONSORED ADS | 07725L102 | $3.0B | 8,799,053 | 21.7% |
| Incyte Corporation(INCY) | COM | 45337C102 | $2.6B | 30,743,663 | 18.8% |
| Madrigal Pharmaceuticals, Inc.(MDGL) | COM | 558868105 | $982.3M | 2,141,701 | 7.1% |
| Insmed Incorporated(INSM) | COM PAR $.01 | 457669307 | $965.4M | 6,703,484 | 7.0% |
| Acadia Pharmaceuticals Inc.(ACAD) | COM | 004225108 | $915.4M | 42,896,690 | 6.6% |
| Summit Therapeutics Inc.(SMMT) | COM | 86627T108 | $696.7M | 33,722,974 | 5.0% |
| Rhythm Pharmaceuticals, Inc.(RYTM) | COM | 76243J105 | $566.0M | 5,604,483 | 4.1% |
| Revolution Medicines, Inc.(RVMD) | COM | 76155X100 | $441.6M | 9,455,357 | 3.2% |
| Celcuity Inc.(CELC) | COM | 15102K100 | $391.0M | 7,915,792 | 2.8% |
| Kymera Therapeutics, Inc.(KYMR) | COM | 501575104 | $376.5M | 6,651,429 | 2.7% |
| Kodiak Sciences Inc.(KOD) | COM | 50015M109 | $283.4M | 17,310,490 | 2.0% |
| Alkermes plc(ALKS) | SHS | G01767105 | $242.7M | 8,091,351 | 1.8% |
| AbCellera Biologics Inc.(ABCL) | COM | 00288U106 | $138.5M | 27,525,640 | 1.0% |
| Edgewise Therapeutics, Inc.(EWTX) | COM | 28036F105 | $118.5M | 7,305,940 | 0.9% |
| Kiniksa Pharmaceuticals International, plc(KNSA) | ORD SHS CL A | G52694109 | $109.7M | 2,824,669 | 0.8% |
| Stoke Therapeutics, Inc.(STOK) | COM | 86150R107 | $108.9M | 4,633,838 | 0.8% |
| Immatics N.V.(IMTX) | SHS | N44445109 | $103.0M | 12,094,094 | 0.7% |
| Grail, Inc.(GRAL) | COM | 384747101 | $96.4M | 1,630,125 | 0.7% |
| Ideaya Biosciences, Inc.(IDYA) | COM | 45166A102 | $89.1M | 3,275,444 | 0.6% |
| Immunovant, Inc.(IMVT) | COM | 45258J102 | $88.0M | 5,457,881 | 0.6% |
| Immunocore Holdings plc(IMCR) | ADS | 45258D105 | $84.4M | 2,322,656 | 0.6% |
| Bicycle Therapeutics plc(BCYC) | SPONSORED ADS | 088786108 | $84.3M | 10,885,357 | 0.6% |
| Ultragenyx Pharmaceutical Inc.(RARE) | COM | 90400D108 | $83.4M | 2,772,692 | 0.6% |
| Abivax S.A.(ABVX) | SPONSORED ADS | 00370M103 | $74.4M | 875,796 | 0.5% |
| Arrowhead Pharmaceuticals, Inc.(ARWR) | COM | 04280A100 | $57.6M | 1,670,762 | 0.4% |
| Roivant Sciences Ltd.(ROIV) | SHS | G76279101 | $57.0M | 3,767,773 | 0.4% |
| Denali Therapeutics Inc.(DNLI) | COM | 24823R105 | $54.2M | 3,731,695 | 0.4% |
| Merus N.V. | COM | N5749R100 | $54.1M | 574,377 | 0.4% |
| Intellia Therapeutics, Inc.(NTLA) | COM | 45826J105 | $47.4M | 2,746,674 | 0.3% |
| Replimune Group, Inc.(REPL) | COM | 76029N106 | $46.3M | 11,045,336 | 0.3% |
| Rapport Therapeutics, Inc.(RAPP) | COM | 75383L102 | $45.9M | 1,547,090 | 0.3% |
| Structure Therapeutics Inc.(GPCR) | SPONSORED ADS | 86366E106 | $43.6M | 1,556,109 | 0.3% |
| Celcuity Inc. | Note 2.75% 8/1/2031 | 15102KAA8 | $40.9M | $30,750,000 | 0.3% |
| Viridian Therapeutics, Inc.(VRDN) | COM | 92790C104 | $37.6M | 1,744,406 | 0.3% |
| Ionis Pharmaceuticals, Inc.(IONS) | COM | 462222100 | $37.1M | 566,798 | 0.3% |
| Praxis Precision Medicines, Inc.(PRAX) | COM | 74006W207 | $36.5M | 689,488 | 0.3% |
| Monte Rosa Therapeutics, Inc.(GLUE) | COM | 61225M102 | $36.4M | 4,916,095 | 0.3% |
| BioNTech SE(BNTX) | SPONSORED ADS | 09075V102 | $36.4M | 368,923 | 0.3% |
| Nurix Therapeutics, Inc.(NRIX) | COM | 67080M103 | $35.9M | 3,882,125 | 0.3% |
| Dianthus Therapeutics, Inc.(DNTH) | COM | 252828108 | $31.1M | 789,759 | 0.2% |
| Entrada Therapeutics, Inc.(TRDA) | COM | 29384C108 | $28.2M | 4,865,819 | 0.2% |
| argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $27.9M | 37,760 | 0.2% |
| Avidity Biosciences, Inc.(RNA) | COM | 05370A108 | $27.2M | 625,000 | 0.2% |
| Vaxcyte, Inc.(PCVX) | COM | 92243G108 | $23.1M | 640,885 | 0.2% |
| Disc Medicine, Inc.(IRON) | COM | 254604101 | $22.3M | 337,050 | 0.2% |
| Cidara Therapeutics, Inc.(CDTX) | COM | 171757206 | $21.8M | 227,272 | 0.2% |
| Celldex Therapeutics, Inc.(CLDX) | COM | 15117B202 | $17.2M | 665,370 | 0.1% |
| Neurogene Inc.(NGNE) | COM | 64135M105 | $17.2M | 991,691 | 0.1% |
| Sera Prognostics, Inc.(SERA) | CLASS A COM | 81749D107 | $16.8M | 5,498,170 | 0.1% |
| Spyre Therapeutics, Inc.(SYRE) | COM | 00773J202 | $16.8M | 1,000,000 | 0.1% |